No Picture
Trading Ideas

Don’t Make This Common but Very Costly Mistake in Retirement!

I consider myself to be an expert of sorts on retirement. Not because I’ve studied the subject, but because I’ve retired three times.
Yes, I’m a three-time failure at retiring. But I’ve learned from my mistakes. Today, I’d like to tell you about the worst mistake retirees make.
It’s a common mistake… yet I’ve never heard it mentioned by retirement experts. Nor have I read a word about it in retirement books…
The biggest mistake retired people make is giving up all their active income.
When I say active income, I mean the money you make through your labor or through a business you …read more […]

No Picture
Trading Ideas

Gilead shares rise after United States approves remdesivir as COVID-19 drug

The U.S. health regulator’s approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients’ length of hospital stay or chances of survival in a global trial. The U.S. Food and Drug Administration’s (FDA) backing signals its confidence in Gilead’s U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note. Remdesivir has been available under an FDA emergency use authorization since May, after a …read more […]

No Picture
Trading Ideas

Ant’s IPO Lures Fidelity, T. Rowe Price, UBS Asset

(Bloomberg) — T. Rowe Price Group Inc., UBS Asset Management and FMR LLC, the parent of Fidelity Investments, are among the money managers angling for a piece of Ant Group Co.’s blockbuster initial public offering, a person familiar with the matter said.Each of the firms is considering investments worth several billion dollars in Ant’s Hong Kong-listed shares, though they’ve yet to finalize plans and there’s no guarantee they’ll get an allocation, the person said, asking not to be identified discussing private information.Ant is expected to start taking orders for the Hong Kong portion of its dual listing on Oct. 26 …read more […]

No Picture
Trading Ideas

Gilead’s Remdesivir Becomes First Virus Treatment to Win FDA Nod

(Bloomberg) — The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.Regulators had granted an emergency-use authorization for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalized Covid-19 patients. It was given to President Donald Trump this month when he was diagnosed with the virus.The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help …read more […]

No Picture
Trading Ideas

Europe Stocks Gain on Earnings; U.S. Futures Drop: Markets Wrap

(Bloomberg) — European stocks opened higher on positive earnings news as traders awaited key manufacturing data for the euro zone. The dollar steadied.Carmaker shares rose in Europe after Germany’s Daimler AG boosted its full-year profit forecast, while bank stocks were buoyed by Barclays Plc’s earnings beat. Swiss elevator maker Schindler Holding AG jumped after boosting its forecast. That left the Stoxx Europe 600 Index headed for its first gain of the week.The euro fell before October’s flash purchasing-managers’ gauges, which are forecast to show weakness in the service and manufacturing sectors. U.S. futures slipped as investors watched prospects fade further …read more […]

No Picture
Trading Ideas

Barclays Thrives on Volatility as Equities Beat Wall Street

(Bloomberg) — Barclays Plc’s traders had another strong quarter as pandemic-driven market volatility persisted.The London-based bank’s securities division reported a 23% jump in foreign-exchange, rates and credit trading income in the third quarter, helping the company beat earnings estimates. Equity trading jumped 40%. Barclays also posted lower-than-expected impairments from the virus crisis.“The economic forecast is more moderate than we would have thought a couple of months ago,” and Britain’s mortgage market is “surprisingly robust,” Chief Executive Officer Jes Staley said Friday in a Bloomberg Television interview. “Capital markets globally will increasingly take a greater share of the financing of economic …read more […]